Merck gets FDA nod for KEYTRUDA to treat squamous cell carcinoma
KEYTRUDA is an anti PD-1 therapy that works by enhancing the body’s immune system to detect and fight…
We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.
ContinueLearn More X
25 Jun 20
KEYTRUDA is an anti PD-1 therapy that works by enhancing the body’s immune system to detect and fight…
23 Jun 20
The regulatory authorisation indicated Qinlock for the treatment of advanced gastrointestinal stromal tumour in adult patients who received…
22 Jun 20
CDSCO granted restricted emergency use of Favipiravir tablets to Glenmark Pharmaceuticals; and Remdesivir injectable formulations to Cipla and…
19 Jun 20
Tazverik is indicated for relapsed or refractory FL in adult patients whose tumours are positive for an EZH2…
17 Jun 20
The US FDA approval for Cosentyx is based on the Phase 3 PREVENT trial, which showed efficacy in…
The FDA has cited evidence of serious side-effects including cardiac-adverse events in patients given chloroquine drugs to treat…
16 Jun 20
Kynmobi demonstrated improvement in motor symptoms for patients with PD compared to placebo in Phase 3 clinical trial
16 Jun 20
Data from the Phase 3 randomised, active-controlled clinical studies PRONTO-T1D and PRONTO-T2D has supported the US regulatory approval…
15 Jun 20
Dolutegravir is an integrase strand transfer inhibitor which, in combination with other antiretroviral agents, has potential to treat…
11 Jun 20
Opdivo is indicated for unresectable advanced, metastatic ESCC after prior fluoropyrimidine- and platinum-based chemotherapy